Zelluna ASA is a biotechnology company that specializes in the development of novel cell therapies for cancer treatment. The company has developed a TCR-NK cell therapy platform that targets solid cancer. This focus is part of their strategy to overcome the specific challenges associated with treating solid cancer, an area that often has unmet medical needs.
Zelluna ASA targets highly valued markets and aims to develop treatments with the potential to "cure" certain types of cancer. Through its innovative therapies, the company contributes to life-saving treatments, and its work can be of great importance to patients facing serious cancer diagnoses.